Hemochromatosis
Aka: Hemochromatosis, Bronze diabetes
II. Epidemiology: Hereditary Hemochromatosis
- Clinically important hereditary Hemochromatosis is rare
- Only 10% of C282Y Homozygotes manifest disease (remainder are asymptomatic)
- Cirrhosis develops in 1-2% of C282Y Homozygotes
- Manifestations are twice as common and more severe in men
- Homozygous C282Y Prevalence varies across ethnicity
- White: 4.4 per 1000
- Hispanic: 0.27 per 1000
- Black: 0.14 per 1000
- Asian American: <0.001 per 1000
- References
III. Etiologies
- Hereditary Hemochromatosis
- General
- Autosomal Recessive disease (HFE Gene)
- Homozygous HFE Incidence: 1 in 250-300 caucasians
- Disrupted iron regulation results in toxic iron accumulation and tissue iron deposition
- HFE protein regulates hepcidin (iron regulatory protein)
- Hepatocytes secrete hepcidin in response to excess iron
- Hepcidin decreases intestinal iron absorption and Macrophage iron release
- Hepcidin expression is decreased in hereditary Hemochromatosis, resulting in excess iron levels
- Chromosome 6 mutations responsible
- C282Y Mutation (90% of cases)
- Homozygous in 0.64% of white patients (Heterozygous in 10%)
- Missense mutation with Tyrosine for cysteine at 282 on Chromosome 6
- H63D Mutation (10% of cases)
- Combination of C282Y/H63D occurs in 2% of white patients
- S65C Mutation
- C282Y Mutation (90% of cases)
- General
- Secondary iron overload
- Chronic Anemia (e.g. Thalassemia major)
- Chronic Liver Disease (e.g. Viral Hepatitis)
- Iron Supplementation (rare with oral iron)
- Multiple transfusions
- Parenteral Iron dextran
IV. Pathophysiology: Hereditary Hemochromatosis
- Inappropriately high intestinal iron absorption
- Only a few extra iron milligrams absorbed each day
- Iron slowly accumulates over decades
- Results in excess body iron stores
- Normal body iron stores: 4 grams
- Exceeded by age 10 in hereditary Hemochromatosis
- Tissue injury occurs when body iron 25 grams (age 30)
- Cirrhosis when body iron 30-40 grams (age 40)
- Normal body iron stores: 4 grams
- Factors that provoke expression of disease
- Male gender (women may be protected due to Menses)
- Hepatitis C
- Alcohol Abuse
- Manifestations
- Organ iron deposition
- Iron deposits in heart, liver and Pancreas, bones and joints
- Results in Cardiomyopathy, Cirrhosis, Diabetes Mellitus and Arthritis
- Increased oxidative DNA and free radical activity
- Hepatocellular Carcinoma risk (20 fold increase risk when Cirrhosis present)
- Breast Cancer risk (variable evidence)
- Organ iron deposition
V. Findings: Presentations
- Classic Presentation – Bronze diabetes (late stage, rare)
- Hyperpigmented skin
- Diabetes Mellitus
- Cirrhosis
- Typical presentations
- Weakness, lethargy and Arthralgias
- Erectile Dysfunction
- Liver Function Test abnormalities
VI. Symptoms (asymptomatic in most cases)
- Common symptoms
- Fatigue, Lassitude, or weakness
- Arthralgias
- Impotence
- Other symptoms
- Weight loss
- Abdominal Pain
- Hyperpigmented skin
VII. Signs
- Brown skin pigmentation
- Hepatomegaly
- Loss of body hair
- Edema
- Ascites
- Peripheral neuritis
- Testicular atrophy
- Synovitis at second and third metacarpophalangeal joints
VIII. Complications
- Cirrhosis
- Associated 20 fold increased lifetime risk of Hepatocellular Carcinoma (4% annual Incidence)
- Diabetes Mellitus
- Arthritis (MCP joints) or Pseudogout
- Hypogonadism
- Hypothyroidism
- Restrictive Cardiomyopathy (reversible if treated before Heart Failure develops)
- Diastolic Dysfunction
- Atrioventricular Block
- Dysrhythmias
- Skin Hyperpigmentation (bronze or gray color)
- Infection
- Vibrio vulnificus
- Listeria monocytogenes
- Pasteurella pseudotuberculosis
IX. Labs: Screening
- Indications for screening
- Generalized weakness
- Arthralgias (especially involving hand joints, MCP joints 2 and 3)
- Hepatomegaly
- Aspartate Aminotransferase (AST) elevation
- Hypogonadism (Impotence or Infertility)
- Skin Hyperpigmentation
- Cardiomyopathy or cardiac arrhythmia
- Diabetes Mellitus
- Family History of Hemochromatosis
- Risk if sibling with Hemochromatosis: 25%
- Risk if parent with Hemochromatosis: 5%
- Iron Saturation (Serum Transferrin Saturation)
- Earliest lab change in hereditary Hemochromatosis
- Previously guidelines recommended Fasting iron tests (or confirmation with Fasting test)
- Fasting is no longer required as non-Fasting values are accurate
- Serum Iron was thought to be impacted by oral intake and presumed most accurate when Fasting
- Test Sensitivity approaches 94% in C282Y Homozygote
- Abnormal levels suggesting Hemochromatosis
- Men >45-50%
- Women >45%
- Serum Ferritin
- Obtain with Iron Saturation
- High Test Sensitivity but poor Specificity
- False positives as an acute phase reactant
- Positive Predictive Value is <18%
- Offers prognostic value
- Abnormal levels suggesting Hemochromatosis
- Men >250-300 ng/ml
- Women > 200 ng/ml
- Obtain with Iron Saturation
X. Labs: Genetic Testing
- Test for C282Y Mutation (Homozygous)
- Indications for testing
- First degree relative of C282Y Homozygote
- Abnormal Serum Ferritin
- Abnormal Transferrin Saturation
XI. Diagnosis: Liver biopsy
- Indications
- Non-hereditary Hemochromatosis
- Late presentation
- Aspartate Aminotransferase (AST) >40 U/L
- Ferritin >1000 ng/ml
- Findings
- Hepatic tissue iron index>2 (tissue iron umoles/age)
- Excessive Hemosiderin deposits
- Site of iron deposition varies per cause
- Hereditary Hemochromatosis: Hepatocytes
- Secondary iron overload: Kupffer cells
XII. Evaluation (If Hemochromatosis screening positive)
- Rule-out secondary cause of iron overload (see above)
- Alcoholic Liver Disease
- Hepatitis C and other Viral Hepatitis
- Exogenous iron intake
- Thalassemia major and other chronic Anemias
- Obtain HFE gene test (consider via Consultation)
- Homozygous for HFE C282Y mutation
- Phlebotomy if liver biopsy indications not met
- Liver biopsy indications
- Increased Aspartate Aminotransferase (AST)
- Serum Ferritin >1000 ng/ml
- Hepatomegaly
- Findings not consistent with hereditary form
- Obtain Liver biopsy (see above) or abdominal MRI
- Phlebotomy for Hemochromatosis liver findings
- Homozygous for HFE C282Y mutation
XIII. Management
- Test ALL first degree relatives
- Phlebotomy
- May be performed at some blood donation centers (requires waiver)
- Remove 500 ml blood weekly (one unit of blood or 200-250 ml pRBC)
- Removes 200-250 mg iron
- Reduces Serum Ferritin by 30 ng/ml
- Goals: Iron depletion (reached in 6 to 24 months)
- Hemoglobin: 12.5 to 13 g/dl (check before each phlebotomy)
- Serum Ferritin: 50 to 150 ng/ml
- Transferrin Saturation <50%
- Expected effects of phlebotomy
- Removes excess iron and normalizes tissue iron stores
- Prevents progression and complications
- Fatigue and lethargy resolve
- Skin bronzing improves
- Cardiac Function and Restrictive Cardiomyopathy improve
- Hepatomegaly and Liver Function Test abnormalities improve (hepatic fibrosis improves in 30% of cases)
- However, Diabetes Mellitus control may be unaffected
- Complications
- Iron avidity
- Results from overcorrection of iron overload
- Presents with iron craving and normal Serum Ferritin with increased Iron Saturation
- Iron avidity
- Dietary recommendations
- Avoid Hepatotoxins including Alcohol
- Avoid exogenous iron sources
- Avoid iron supplements
- Avoid Multivitamins with iron
- Avoid Vitamin C Supplementation
- Limit red meat intake
- However unlikely to have significant impact at typically <4 mg Dietary Iron per day
- Avoid exposure to Vibrio vulnificus
- Avoid raw seafood intake
- Do not handle raw seafood
XIV. Management: Cirrhosis
- Predictors of Cirrhosis development (each factor increases risk in succession up to risk >80%)
- Increased Serum Ferritin over 1000 ng/ml
- Increased hepatic transaminases (ALT or AST)
- Decreased Platelet Count <200k
- Excessive alchol use (>60 grams per day or 4 drinks per day)
- Refer to gastroenterology for signs of Cirrhosis
- Surveillance for Hepatocellular Carcinoma
- Consideration for liver transplantation
- Surveillance for Hepatocellular Carcinoma
- Obtain RUQ Ultrasound
- No Liver Lesion
- RUQ Ultrasound every 6-12 months
- Liver Lesion <1 cm
- RUQ Ultrasound every 3-6 months
- Gastroenterology consult
- Liver Lesion >1 cm
- Evaluate for Hepatocellular Carcinoma
- Gastroenterology consult
XV. Prognosis: Conditions increasing mortality
- Cirrhosis (5 year survival reduced 50%)
- Diabetes Mellitus
- Restrictive Cardiomyopathy with Heart Failure